MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

TACE

  • Home
  • TACE
Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy
Posted inGastroenterology news Oncology

Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy

Posted by By MedXY 04/02/2026
A groundbreaking multicentre study develops a clinical-radiologic model integrating hypoxia and immune phenotype signatures to accurately predict prognosis in hepatocellular carcinoma patients treated with transarterial chemoembolisation, potentially transforming personalised treatment strategies.
Read More
Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma
Posted inGastroenterology news Oncology

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma

Posted by By MedXY 10/27/2025
This review explores how gut microbiota disturbances, especially L. reuteri and its metabolite ILA, influence post-TACE liver injury and prognosis in HCC patients, highlighting potential microbiota-targeted therapies.
Read More
  • Enhancing Inter-Visit Care in Internal Medicine Residency: Integrating Structural Support and Educational Curriculum
  • Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing Homes: A Comprehensive Review
  • Periconceptional Vitamin B12 and Folate Levels in Parents Linked to Birth Defect Risk Reduction: Insights from a Large Prospective Cohort
  • TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation
  • Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top